US Stock Market Closed

Dashboard

Tenax Therapeutics, Inc. (TENX)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity
Analyst Opinion

S

Leverage & Liquidity

H

Fundamental Variables

Rating Performance

FV Performance

About

Tenax Therapeutics, Inc. engages in the identification, development, and commercialization of novel therapeutic products for the critical care market. Its lead product candidate is Levosimendan, a calcium sensitizer activator for intravenous use in hospitalized patients with acutely decompensated heart failure. The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.

CEO

Anthony A. DiTonno

Employees

9

Industry

-

Sector

-

Headquarters

Morrisville

Exchange

NASDAQ

Summary Stats

Market Cap

5.1M

Revenue

-

Net Income

-

EPS

$0.00

Price-to-Earnings

-

Price-to-Book

-

Debt-to-Equity

-

News

Analyst Ratings

Price targets projected by 2 analysts

High

$4.00

Average

$3.00

Low

$2.00

Ratings calculated by 0 analysts

Buy

0

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Missed by -$0.20

Actual

-$2.20 -10.0%

Consensus

-2.0

Report Date

Year Ago

-0.15

Year Ago Change %

Down 1366%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites